136 related articles for article (PubMed ID: 35763868)
1. Identification of (S)-1-(2-(2,4-difluorophenyl)-4-oxothiazolidin-3-yl)-3-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)urea as a potential anti-colorectal cancer agent.
Qi B; Wang F; He H; Fan M; Hu L; Xiong L; Gong G; Shi S; Song X
Eur J Med Chem; 2022 Sep; 239():114561. PubMed ID: 35763868
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel quinoline analogues bearing thiazolidinones as potent kinase inhibitors for the treatment of colorectal cancer.
Zhou Y; Xu X; Wang F; He H; Gong G; Xiong L; Qi B
Eur J Med Chem; 2020 Oct; 204():112643. PubMed ID: 32731184
[TBL] [Abstract][Full Text] [Related]
3. Discovery of N
Qi B; Yang Y; Gong G; He H; Yue X; Xu X; Hu Y; Li J; Chen T; Wan X; Zhang A; Zhou G
Eur J Med Chem; 2019 Feb; 163():10-27. PubMed ID: 30503936
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 4-((4-(4-(3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)ureido)-2-fluorophenoxy)-6-methoxyquinolin-7-yl)oxy)-N,N-diethylpiperidine-1-carboxamide as kinase inhibitor for the treatment of colorectal cancer.
Zhou Y; Xu X; Wang F; He H; Qi B
Bioorg Chem; 2021 Jan; 106():104511. PubMed ID: 33272707
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel conjugates of quinoline and thiazolidinone urea as potential anti-colorectal cancer agent.
Xiong L; He H; Fan M; Hu L; Wang F; Song X; Shi S; Qi B
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2334-2347. PubMed ID: 36043496
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives.
El-Damasy AK; Seo SH; Cho NC; Kang SB; Pae AN; Kim KS; Keum G
Eur J Med Chem; 2015 Aug; 101():754-68. PubMed ID: 26218653
[TBL] [Abstract][Full Text] [Related]
8. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
Nan X; Li HJ; Fang SB; Li QY; Wu YC
Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7.
Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM
Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic and Apoptotic Effects of Novel Pyrrolo[2,3-d]Pyrimidine Derivatives Containing Urea Moieties on Cancer Cell Lines.
Kilic-Kurt Z; Bakar-Ates F; Karakas B; Kütük Ö
Anticancer Agents Med Chem; 2018; 18(9):1303-1312. PubMed ID: 29866023
[TBL] [Abstract][Full Text] [Related]
11. A New Series of Antileukemic Agents: Design, Synthesis, In Vitro and In Silico Evaluation of Thiazole-Based ABL1 Kinase Inhibitors.
Zeytün E; Altıntop MD; Sever B; Özdemir A; Ellakwa DE; Ocak Z; Ciftci HI; Otsuka M; Fujita M; Radwan MO
Anticancer Agents Med Chem; 2021; 21(9):1099-1109. PubMed ID: 32838725
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
Luo G; Ma Y; Liang X; Xie G; Luo Y; Zha D; Wang S; Yu L; Zheng X; Wu W; Zhang C
Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.
Wang Z; Shi J; Zhu X; Zhao W; Gong Y; Hao X; Hou Y; Liu Y; Ding S; Liu J; Chen Y
Bioorg Chem; 2020 Dec; 105():104371. PubMed ID: 33075664
[TBL] [Abstract][Full Text] [Related]
14. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
[TBL] [Abstract][Full Text] [Related]
15. Structural optimization of 4-(imidazol-5-yl)pyridine derivatives affords broad-spectrum anticancer agents with selective B-RAF
Ali EMH; Mersal KI; Ammar UM; Zaraei SO; Abdel-Maksoud MS; El-Gamal MI; Haque MM; Das T; Kim EE; Lee JS; Lee KH; Kim HK; Oh CH
Eur J Pharm Sci; 2022 Apr; 171():106115. PubMed ID: 34995782
[TBL] [Abstract][Full Text] [Related]
16. Quinoline-based thiazolidinone derivatives as potent cytotoxic and apoptosis-inducing agents through EGFR inhibition.
Nafie MS; Kishk SM; Mahgoub S; Amer AM
Chem Biol Drug Des; 2022 Apr; 99(4):547-560. PubMed ID: 34873844
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Biological Evaluation of 4-Phenoxyquinoline Derivatives Containing Benzo[d]thiazole-2-yl Urea as c-Met Kinase Inhibitors.
Lei H; Hu G; Wang Y; Han P; Liu Z; Zhao Y; Gong P
Arch Pharm (Weinheim); 2016 Aug; 349(8):651-61. PubMed ID: 27283017
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore-based virtual screening, synthesis, biological evaluation, and molecular docking study of novel pyrrolizines bearing urea/thiourea moieties with potential cytotoxicity and CDK inhibitory activities.
Shawky AM; Ibrahim NA; Abourehab MAS; Abdalla AN; Gouda AM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):15-33. PubMed ID: 33103497
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Zou M; Li J; Jin B; Wang M; Chen H; Zhang Z; Zhang C; Zhao Z; Zheng L
Bioorg Chem; 2021 Sep; 114():105200. PubMed ID: 34375195
[TBL] [Abstract][Full Text] [Related]
20. Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor.
Sun Y; Wang L; Sun Y; Wang J; Xue Y; Wu T; Yin W; Qin Q; Sun Y; Wang H; Gao Y; Yang H; Zhao D; Cheng M
Eur J Med Chem; 2022 Dec; 243():114714. PubMed ID: 36063666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
